Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,223,237 papers from all fields of science
Search
Sign In
Create Free Account
losoxantrone
Known as:
7-hydroxy-2(2-((2-hydroxyethyl) amino) ethyl)5-(2-((2-hydroxyethyl)amino)ethyl)amino anthra(1,9-cd)pyrazole-6(2H)-one
An anthrapyrazole-based antineoplastic antibiotic. Losoxantrone intercalates into DNA, induces single- and double-stranded DNA breaks and inhibits…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
10 relations
Broader (3)
Anthraquinones
Antineoplastic Agents
Pyrazolones
Narrower (3)
Biantrazole
CI 941
DuP 941
Losoxantrone Hydrochloride
NSC 357885
anthrapyrazolone
cyclophosphamide/losoxantrone
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
The oxidative biotransformation of losoxantrone (CI-941).
U. Renner
,
G. Piperopoulos
,
R. Gebhardt
,
G. Ehninger
,
K. Zeller
Drug Metabolism And Disposition
2002
Corpus ID: 7733104
The oxidative biotransformation of the anticancer drug 7-hydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-[(2-hydroxyethyl)amino…
Expand
Review
2001
Review
2001
Separation methods for anthraquinone related anti-cancer drugs.
P. Loadman
,
C. Calabrese
Journal of Chromatography B: Biomedical Sciences…
2001
Corpus ID: 19292576
2001
2001
DNA-interactive anticancer aza-anthrapyrazoles: biophysical and biochemical studies relevant to the mechanism of action.
C. Sissi
,
S. Moro
,
+6 authors
M. Palumbo
Molecular Pharmacology
2001
Corpus ID: 9197256
The physicochemical and DNA-binding properties of anticancer 9-aza-anthrapyrazoles (9-aza-APs) were investigated and compared…
Expand
2000
2000
A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer.
S. Huan
,
R. Natale
,
+5 authors
M. Finizio
Clinical Cancer Research
2000
Corpus ID: 9672428
Our purpose in this study was to determine the efficacy and toxicity of losoxantrone (DuP-941), an anthrapyrazole, in patients…
Expand
1999
1999
Stimulation of topoisomerase II-mediated DNA cleavage by an indazole analogue of lucanthone.
L. Dassonneville
,
C. Bailly
Biochemical Pharmacology
1999
Corpus ID: 23347163
Review
1999
Review
1999
Monotherapy of metastatic breast cancer: a review of newer agents.
C. Vogel
,
J. Nabholtz
The Oncologist
1999
Corpus ID: 6338884
PURPOSE New agents for the palliative treatment of metastatic breast cancer have emerged in the 1990s. This review summarizes the…
Expand
1999
1999
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
S. Diab
,
S. Baker
,
+12 authors
E. Rowinsky
Clinical Cancer Research
1999
Corpus ID: 27749346
A Phase I and pharmacological study was performed to evaluate the feasibility, maximum tolerated dose (MTD), dose-limiting…
Expand
1996
1996
Validation of cleaning procedures for highly potent drugs. I. Losoxantrone.
J. A. Shea
,
W. Shamrock
,
+4 authors
J. Segretario
Pharmaceutical development and technology (Print)
1996
Corpus ID: 36364424
The validation of a procedure designed to clean glass and stainless steel surfaces after exposure to the experimental anticancer…
Expand
Highly Cited
1994
Highly Cited
1994
Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen.
F. Leteurtre
,
G. Kohlhagen
,
K. Paull
,
Y. Pommier
Journal of the National Cancer Institute
1994
Corpus ID: 23975117
BACKGROUND The cumulative cardiotoxicity of anthracyclines is thought to result from the generation of free radicals. New DNA…
Expand
Review
1994
Review
1994
New chemotherapeutic agents for breast cancer
J. Abrams
,
T. Moore
,
M. Friedman
Cancer
1994
Corpus ID: 25621940
The drug discovery programs of the National Cancer Institute and the pharmaceutical industry recently have provided oncologists…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE